Sunday, April 17, 2022

Rilzabrutinib for blood disorder shows promise in phase 1--2 clinical trial

In an international phase 1--2 clinical trial of patients with immune thrombocytopenia, an oral investigational drug called rilzabrutinib was active and associated with only low-level toxic effects at all dose levels.

from Latest Science News -- ScienceDaily https://ift.tt/a1xsB4d
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Study finds untreated sleep apnea doubles Parkinson’s risk

A massive veteran study found a strong connection between untreated sleep apnea and a higher chance of Parkinson’s. CPAP users had much lowe...